Personalized Medicines Market
Report ID: SQMIG35H2307
Report ID: SQMIG35H2307
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2307 |
Region:
Global |
Published Date: November, 2024
Pages:
209
|Tables:
65
|Figures:
70
Global Personalized Medicines Market size was valued at USD 560.49 Billion in 2024 and is poised to grow from USD 612.62 Billion in 2025 to USD 1247.81 Billion by 2033, growing at a CAGR of 9.3% during the forecast period (2026-2033).
Key Takeaways: Market Trends & Insights
Personalized medicine amalgams medicine with genetic technology to facilitate specific treatment unique to each patient. Human genomes are unique to each individual hence the impact of the diseases also varies for each patient hence personalized medicines aim to provide personalized diagnosis and treatment to each patient. The demand for personalized medicines is significant for diagnosis and treatment of cancer. However, with the development and growing availability of genetic technology demand for non-oncology application for personalized medicines is also on the rise.
Genetic technology has been witnessing double digit growth rate and the investment in this field is also increasing steadily. Innovations in the field of genetic technology are paving the way for the application of personalized medicine for the treatment of rare diseases. Research on the application of personalized medicine for the diagnosis and treatment of Alzheimer’s and Parkinson’s disease has gained momentum and this trend is expected to continue in the medium to long term. The healthcare industry has been slow adopted of technology. However, with the increasing healthcare budgets and growing collaborations between pharma companies and government agencies it is expected to further boost the demand for personalized medicine.
To get more insights on this market click here to Request a Free Sample Report
Global Personalized Medicines Market is segmented by Product, Technology, Mode of Delivery, Therapeutic Area, Application, End-User and region. Based on Product, the market is segmented into Diagnostics, Therapeutics, Personalized Medical Care and Personalized Nutrition and Wellness. Based on Technology, the market is segmented into Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy and Others. Based on Mode of Delivery, the market is segmented into In-Hospital Personalized Treatment, Home-Based Testing & Treatment, Telemedicine Platforms, Point-of-Care Diagnostics and Others.
Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Rare & Genetic Disorders, Autoimmune Diseases, Infectious Diseases, Endocrinology and Others. Based on Application, the market is segmented into Drug Discovery & Development, Clinical Decision Making, Risk Assessment & Disease Prediction, Therapy Selection & Monitoring, Preventive Healthcare and Others. Based on End-User, the market is segmented into Hospitals, Diagnostic Centers, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on product, the market is segmented into personalized medicine diagnostics, genetic testing, direct-to-consumer (DTC) diagnostics, and esoteric lab services. The personalized medicine diagnostics segment is dominating the personalized medicines market with the largest market revenue share. Demand for personalized medicines diagnostic is significantly high due to its extensive application in oncology. Cancer can be fatal and has one of the highest morbidity rates among diseases. Use of personalized medicine diagnosis for detection and treatment of target malignant tissue growth is high. Lower side effects and widespread acceptance of personalized medicine diagnostics for cancer treatment in developed economies is expected to fuel the demand for this segment.
The genetic testing products segment is expected to witness higher growth during the forecast period. Personalized medicines are widely suggested and accepted in the case of diagnosis and treatment of rare diseases. The number of detected rare disease and cases of each rare disease is on the rise yet the healthcare professionals are yet to unearth actual causes and treatment of large number of rare diseases. Hence the use of genome study and gene technology for the study of rare diseases is substantially high. A large number of government organizations are collaborating with pharmaceutical companies to expand the horizon of genetic testing.
In terms of end-use, the demand for personalized medicine is segmented into hospitals, diagnostic centers, research & academic institutes, and others. The demand for personalized medicine is largest for hospital end-use. Growth in the network of hospitals globally in the past few decades has boosted demand. Higher footfall of patients in hospitals and availability of better infrastructure in hospitals in comparison to other medical facilities has resulted in significant high demand for this segment. More than 50% of the reported cases of rare and critical diseases are treated in hospitals hence the demand for alternate medicine including personalized medicine is significantly high in hospitals.
The demand for personalized medicines is expected to grow the fastest for diagnostic center end-use during the forecast period. The diagnostic industry has been growing exponentially, witnessing an almost double-digit growth rate in the past few years. The diagnostic industry has adopted well to the implementation of technology such as artificial intelligence and genetic technology. The growing number of multi-specialty diagnostic centers in developing regions fueled by high degree of competition is expected to boost the technology adoption among diagnostic industry. This will directly increase the demand for personalized medicines and the diagnostic center end-user is expected to be the fastest growing segment across all regions.
To get detailed segments analysis, Request a Free Sample Report
North America is dominating the personalized medicines market due to higher healthcare expenditure and developed healthcare service offerings. In 2022, per capital healthcare expenditure in the US was more than USD 13,000 which is one of the highest globally. In addition, government healthcare expenditure is also significantly high in North America. In 2022, the US spent most of the country's GDP on the healthcare sector. Due to the higher expenditure coupled with the ease of availability the demand for personalized medicine is the highest in North America and this trend is expected to continue during the forecast period. These factors are increasing the growth of personalized medicines market in the region.
Demand for personalized medicines is expected to grow the fastest in the Asia Pacific region. Improving healthcare infrastructure coupled with the expansion of major pharmaceutical and healthcare companies in the region is expected to fuel the growth in the region. A large number of pharmaceutical companies are expanding their operations and manufacturing hubs to Asia Pacific due to rising end use demand and low cost of production including lower cost of clinical trial.
The median cost incurred by pharmaceutical companies to develop a drug, conduct clinic trials and get FDA approval in the US is in the range of USD 50 million. This is significantly high in comparison to its Asian counterparts. Thus, the demand for personalized medicine will witness a significant uptick in demand in the region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancement in Genetic Technology
Growing Prevalence of Rare Disease
Expensive Healthcare
Poor Technology Implementation
Request Free Customization of this report to help us to meet your business objectives.
There is a high entry barrier in the personalized medicine market due to regulations and high capital investment. Global players are more inclined towards the development and implementation of cutting-edge technology-based products and solutions. While the emerging players are regionally restricted and focus on launching their products in a specific country. There is a high degree of collaboration in the market not only between the players but also between the private enterprise and government agencies. We expect a higher degree of merger and acquisition activities during the forecast period.
Better Insurance Coverage
Increasing Healthcare Budget
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global personalized medicines market is extremely opportunistic and competitive due to higher growth potential in terms of technology and product development. It is an extensive capital market with major players investing significant resources in R&D, and as a result we expect more product and service diversity during the forecast period.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 560.49 Billion |
| Market size value in 2033 | USD 1247.81 Billion |
| Growth Rate | 9.3% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Personalized Medicines Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Personalized Medicines Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Personalized Medicines Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Personalized Medicines Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Personalized Medicines Market size was valued at USD 560.49 Billion in 2024 and is poised to grow from USD 612.62 Billion in 2025 to USD 1247.81 Billion by 2033, growing at a CAGR of 9.3% during the forecast period (2026–2033).
Key vendors in the Personalized Medicines Market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V.. These companies are advancing personalized medicine through targeted therapies, companion diagnostics, genomic sequencing technologies, and precision healthcare solutions across oncology, rare diseases, and other therapeutic areas.
The key driver of the Personalized Medicines Market is the growing adoption of precision medicine supported by advances in genomics and molecular diagnostics. Increasing prevalence of cancer and genetic disorders, rising demand for targeted therapies, and expanding use of companion diagnostics are enabling more effective, patient-specific treatment approaches and driving market growth.
The key market trend in the Personalized Medicines Market is the increasing integration of artificial intelligence (AI), genomic sequencing, and companion diagnostics into precision healthcare. Advances in biomarker discovery, multi-omics technologies, and data-driven treatment selection are enabling highly personalized therapies, improving clinical outcomes, and accelerating the development of targeted medicines across multiple disease areas.
North America accounted for the largest share in the Personalized Medicines Market due to its advanced healthcare infrastructure, strong adoption of precision medicine, substantial investments in genomics research, and the presence of leading pharmaceutical and biotechnology companies. Widespread use of companion diagnostics, favorable reimbursement policies, and increasing demand for targeted therapies further support the region's market leadership.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
